spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Aminopyridine 

 HSMN NewsFeed - 5 Sep 2012
BioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2011
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2010
Biogen Idec Issues Statement on U.S. Approval of AMPYRA (dalfampridine)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Jan 2010
Acorda Therapeutics Announces FDA Approval of AMPYRA (dalfampridine) to Improve Walking in People with Multiple Sclerosis - Demonstrated by Increases in Walking Speed
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Nov 2009
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 20 Sep 2008
Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2008
Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Apr 2008
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2008
Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre-Clinical Assets from Neurorecovery, Inc.
Biopharmaceuticals Acquisitions Neurology
 HSMN NewsFeed - 6 Jun 2007
Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 May 2007
Acorda Therapeutics and FDA Reach Agreement on Special Protocol Assessment for Second Phase 3 Study of Fampridine-SR in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Dec 2006
Neurorecovery, Inc. Receives Orphan Drug Designation
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Dec 2006
Neurorecovery, Inc. Updates Clinical Development Program for Guillain-Barré Syndrome (GBS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Sep 2006
Acorda Therapeutics Announces Positive Results of Phase 3 Study of Fampridine-SR on Walking in People with Multiple Sclerosis
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
Aminopyridine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.